Plus Therapeutics Plunges 14.13% on Q1 Earnings Miss

Before the BellTuesday, Jun 3, 2025 7:29 am ET

1min read

PSTV0.00%

Plus Therapeutics' stock experienced a significant drop of 14.13% in pre-market trading on June 3, 2025, marking a notable decline in its share price.

Plus Therapeutics reported a substantial loss of $17.4 million in its first quarter, which contributed to the decline in its stock price. The company's earnings miss was a key factor in the market's negative reaction, as investors had anticipated better financial performance.

The company's Q1 financial results, released on May 30, highlighted the earnings miss and recent business developments. This news further impacted investor sentiment, leading to the pre-market drop in stock price.

Looking ahead, Plus Therapeutics is scheduled to report its Q2 earnings on August 13, 2025. Investors will be closely monitoring the company's performance in the coming quarters to gauge its recovery and future prospects.

Comments

﻿

Add a public comment...

No comments yet

Disclaimer: The news articles available on this platform are generated in whole or in part by artificial intelligence and may not have been reviewed or fact checked by human editors. While we make reasonable efforts to ensure the quality and accuracy of the content, we make no representations or warranties, express or implied, as to the truthfulness, reliability, completeness, or timeliness of any information provided. It is your sole responsibility to independently verify any facts, statements, or claims prior to acting upon them. Ainvest Fintech Inc expressly disclaims all liability for any loss, damage, or harm arising from the use of or reliance on AI-generated content, including but not limited to direct, indirect, incidental, or consequential damages.